Search Result

Results for "

HDAC degraders

" in MedChemExpress (MCE) Product Catalog:

By Targets:	HDAC (83) Akt (2) AMPK (2) Amyloid-β (1) Apoptosis (23) Aurora Kinase (1) Autophagy (17) Bcl-2 Family (2) Bcr-Abl (1) ByeTAC (1) Caspase (2) DNA/RNA Synthesis (2) Drug Derivative (1) E3 Ligase Ligand-Linker Conjugates (3) Endogenous Metabolite (14) GLUT (1) Histone Demethylase (2) HIV (14) HSP (1) IFNAR (1) IKK (1) Interleukin Related (4) Isotope-Labeled Compounds (4) Ligands for E3 Ligase (2) Ligands for Target Protein for PROTAC (9) MDM-2/p53 (2) Mitophagy (14) Molecular Glues (1) mTOR (1) NEKs (1) NF-κB (2) NO Synthase (1) NOD-like Receptor (NLR) (3) Notch (14) Organoid (6) PD-1/PD-L1 (1) PI3K (2) PINK1/Parkin (2) PROTACs (39) Reactive Oxygen Species (ROS) (5) Reference Standards (2) Target Protein Ligand-Linker Conjugates (3) Tau Protein (1) TNF Receptor (1) Virus Protease (1) Wnt (1) β-catenin (1)
By Research Areas:	Cancer (79) Cardiovascular Disease (2) Infection (9) Inflammation/Immunology (11) Metabolic Disease (7) Neurological Disease (11)
Click Chemistry:	Azide (2) Alkynes (2)

Inhibitors & Agonists

Fluorescent Dyes

Biochemical Assay Reagents

Natural
Products

Isotope-Labeled Compounds

Click Chemistry

GMP Molecules

Targets Recommended: HDAC

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-10585

Valproic acid Maximum Cited Publications 65 Publications Verification VPA; 2-Propylpentanoic acid; Dipropylacetic acid	Organoid HDAC Autophagy Mitophagy HIV Notch Apoptosis Endogenous Metabolite	Infection Neurological Disease Metabolic Disease Inflammation/Immunology Cancer
Valproic acid (VPA) is an orally active *HDAC* inhibitor, with IC₅₀ in the range of 0.5 and 2 mM. Valproic acid inhibits *HDAC1* (IC₅₀, 400 μM), and induces proteasomal degradation of *HDAC2. Valproic acid activates Notch1* signaling and inhibits proliferation in small cell lung cancer (SCLC) cells. Valproic acid is used in the epilepsy, bipolar disorder, metabolic disease, HIV infection and prevention of migraine headaches .

HY-10585A

Valproic acid sodium Maximum Cited Publications 65 Publications Verification Sodium Valproate; VPA sodium; 2-Propylpentanoic acid sodium	Organoid HDAC Autophagy Mitophagy HIV Notch Apoptosis Endogenous Metabolite	Infection Neurological Disease Metabolic Disease Cancer
Valproic acid (Sodium Valproate) sodium is an orally active *HDAC* inhibitor, with IC₅₀ in the range of 0.5 and 2 mM, also inhibits *HDAC1* (IC₅₀, 400 μM), and induces proteasomal degradation of *HDAC2. Valproic acid sodium activates Notch1* signaling and inhibits proliferation in small cell lung cancer (SCLC) cells. Valproic acid sodium is used in the treatment of epilepsy, bipolar disorder, metabolic disease, HIV infection and prevention of migraine headaches .

HY-132998

HDAC6 degrader-1	PROTACs HDAC	Cancer
HDAC6 degrader-1 (Compound NP8) is the PROTAC degrader for *HDAC6* with a DC₅₀ of 3.8 nM in cell MM.1S .(Blue: ligand for E3 ligase Pomalidomide (HY-10984); Black: linker (HY-140213); Pink: ligand for target protein Nexturastat A (HY-16699))

HY-126147

J22352	HDAC	Cancer
J22352 is a PROTAC (proteolysis-targeting chimeras)-like and highly selective *HDAC6* inhibitor with an IC₅₀ value of 4.7 nM. J22352 promotes HDAC6 degradation and induces anticancer effects by inhibiting autophagy and eliciting the antitumor immune response in glioblastoma cancers, and leading to the restoration of host antitumor activity by reducing the immunosuppressive activity of PD-L1 .

HY-164233

YX968	PROTACs HDAC Apoptosis	Cancer
YX968 is a potent and selective *HDAC3/8* PROTAC dual degrader with DC₅₀ values of 1.7 and 6.8 nM. YX968 exhibits antitumor activity by promoting apoptosis .(Pink: Target protein ligand (HY-168287); Black: linker (HY-W007700); Blue: E3 ligase ligand (HY-112078))

HY-152134

HDAC6 degrader-3	HDAC PROTACs	Cancer
HDAC6 degrader-3 is a potent and selective *HDAC6* degrader via ternary complex formation and the ubiquitin-proteasome pathway with a DC₅₀ value of 19.4 nM. HDAC6 degrader-3 has IC₅₀s of 4.54 nM and 0.647 μM for HDAC6 and HDAC1, respectively. HDAC6 degrader-3 causes strong hyperacetylation of α-tubulin .

HY-10585S

Valproic acid-d4 1 Publications Verification VPA-d₄; 2-Propylpentanoic acid-d₄	HDAC Autophagy Mitophagy HIV Notch Endogenous Metabolite	Cancer
Valproic acid-d₄ is the deuterium labeled Valproic acid. Valproic acid (VPA; 2-Propylpentanoic Acid) is an HDAC inhibitor, with IC₅₀ in the range of 0.5 and 2 mM, also inhibits HDAC1 (IC₅₀, 400 μM), and induces proteasomal degradation of HDAC2. Valproic acid activates Notch1 signaling and inhibits proliferation in small cell lung cancer (SCLC) cells. Valproic acid sodium salt is used in the treatment of epilepsy, bipolar disorder and prevention of migraine headaches .

HY-10585S1

Valproic acid-d6 VPA-d₆; 2-Propylpentanoic acid-d₆	HDAC Autophagy Mitophagy HIV Notch Endogenous Metabolite	Cancer
Valproic acid-d₆ is the deuterium labeled Valproic acid. Valproic acid (VPA; 2-Propylpentanoic Acid) is an HDAC inhibitor, with IC₅₀ in the range of 0.5 and 2 mM, also inhibits HDAC1 (IC₅₀, 400 μM), and induces proteasomal degradation of HDAC2. Valproic acid activates Notch1 signaling and inhibits proliferation in small cell lung cancer (SCLC) cells. Valproic acid sodium salt is used in the treatment of epilepsy, bipolar disorder and prevention of migraine headaches .

HY-172762

S234984	HDAC Molecular Glues Histone Demethylase	Cancer
S234984 is a molecular glue degrader. S234984 forms a stable ternary complex with wild-type KBTBD4 E3 ligase and *HDAC2* to drive neomorphic ubiquitination and degradation of CoREST1 and LSD1. S234984 can be used for the research of medulloblastoma .

HY-10585R

Valproic acid (Standard) 45+ Cited Publications VPA (Standard); 2-Propylpentanoic acid (Standard); Dipropylacetic acid (Standard)	Reference Standards Organoid HDAC Autophagy Mitophagy HIV Notch Apoptosis Endogenous Metabolite	Infection Neurological Disease Metabolic Disease Cancer
Valproic acid (Dipropylacetic Acid) (Standard) is an analytical standard for valproic acid. This product is intended for research and analytical applications. Valproic acid is an orally active *HDAC* inhibitor (IC₅₀=0.5-2 mM), inhibits the activity of *HDAC1* (IC₅₀=400 μM), and induces the degradation of *HDAC2. Valproic acid activates Notch1* signaling and inhibits the proliferation of small cell lung cancer (SCLC) cells. Valproic acid is used in the study of epilepsy, bipolar disorder, metabolic diseases, HIV infection, and migraine .

HY-152147

SZUH280	PROTACs HDAC Apoptosis DNA/RNA Synthesis	Cancer
SZUH280 is a potent and selective PROTAC HDAC8 degrader with a DC₅₀ of 0.58 μM in A549 cells. SZUH280 induces cancer cell apoptosis. SZUH280 hampers DNA damage repair in cancer cells, promoting cellular radiosensitization .

HY-174444A

*PROTAC HDAC* degrader-2 TFA**	PROTACs HDAC	Cancer
PROTAC HDAC degrader-2 TFA is the trifluoroacetate salt of PROTAC HDAC degrader-2. PROTAC HDAC degrader-2 is a selective *IIb HDACs* PROTAC** degrader, with DC₅₀s of 13 nM for *HDAC6, 29 nM for HDAC10, respectively. PROTAC HDAC* degrader-2 exhibits low cytotoxicity against hematological and solid cancer cell lines. PROTAC HDAC degrader-2 can be used for the chemical knockdown of class IIb HDACs. ( Pink: HDAC ligand : (HY-174471), Blue: E3 ligase CRBN Ligand (HY-131717), E3 ligase ligand-linker conjugate (HY-174473)) .

HY-145819

JPS036	HDAC PROTACs	Cancer
JPS036 is a benzamide-based Von Hippel-Lindau (VHL) E3-ligase proteolysis targeting chimeras (PROTAC). JPS036 degrades class I histone deacetylase (HDAC). JPS036 is potent HDAC1/2 degrader correlated with greater total differentially expressed genes and enhanced apoptosis in HCT116 cells .

HY-173266A

TO-1187 TFA	PROTACs HDAC	Neurological Disease Cancer
TO-1187 TFA is a selective *HDAC6* PROTAC degrader (DC₅₀: 5.81 nM). TO-1187 TFA promotes the ubiquitination and degradation of HDAC6 and can be used in the study of hematological malignancies and solid tumors (Pink: HDAC6 ligand (HY-173386); Blue: CRBN ligase ligand (HY-41547); Black: linker (HY-140212)) .

HY-146346

HD-TAC7	PROTACs HDAC	Inflammation/Immunology
HD-TAC7 is a potent PROTAC HDAC degrader with IC₅₀ values of 3.6 μM, 4.2 μM and 1.1 μM for HDAC1, HDAC2 and HDAC3, respectively. HD-TAC7 can decreases NF-κB p65 in RAW 264.7 macrophages. HD-TAC7 can be used for the research of inflammatory diseases like asthma and chronic obstructive pulmonary disease (COPD) .

HY-145816A

JPS016 TFA 1 Publications Verification	HDAC PROTACs Apoptosis PINK1/Parkin Autophagy Reactive Oxygen Species (ROS)	Cancer
JPS016 TFA is a class I histone deacetylase (HDAC) PROTAC inhibitor. JPS016 TFA recruits the VHL E3 ligase (Ligands for E3 Ligase) to mediate the ubiquitination and proteasomal degradation of *HDAC1, HDAC2* and *HDAC3. JPS016 TFA reduces the viability of colon cancer cells and induces Apoptosis. JPS016 TFA activates the PINK1/Parkin* mitochondrial Autophagy pathway, enhances cardiomyocyte viability, alleviates mitochondrial damage, and reduces mitochondrial ROS production in cells. JPS016 TFA is applicable to research related to colon cancer and sepsis cardiomyopathy .

HY-N0857

Deoxyandrographolide 1 Publications Verification	GLUT HDAC Virus Protease PI3K AMPK Akt Histone Demethylase MDM-2/p53 IFNAR Reactive Oxygen Species (ROS)	Infection Metabolic Disease Inflammation/Immunology
Deoxyandrographolide is an orally active lactone found in the Andrographis paniculata Nees. Deoxyandrographolide shows a K_D of 38.4 μM of *HDAC1. Deoxyandrographolide enhances GLUT4* plasma membrane translocation, activates PI3K and AMPK-dependent signaling pathways, suppresses fasting blood glucose, serum insulin, triglycerides, and LDL-cholesterol levels. Deoxyandrographolide enhances HDAC1 expression via inhibited ubiquitination degradation, represses H3K4me3, improves chromosome stability, and restrains aging biomarkers p16, p21, γH2A.X, p53 and ROS production. Deoxyandrographolide interacts with Foot-and-Mouth Disease Virus 3Cpro active site, inhibits protease and IFN-antagonist activity, derepresses ISG expression, and inhibits viral replication. Deoxyandrographolide can be used for the researches of type 2 diabetes mellitus, vascular senescence and virus infection .

HY-178161

HDAC degrader-2	HDAC Apoptosis	Cancer
HDAC degrader-2 is a selective *HDAC* degrader with a DC₅₀ values of 2.55 μM against *HDAC1. HDAC* degrader-2 effectively induces the degradation of *HDAC1* and *HDAC2, but has no significant effect on the degradation* of HDAC3, 4, 6 and 8. HDAC degrader-2 exerts potent antiproliferative effects against MM.1S and MCF-7 cells. HDAC degrader-2 induces apoptosis in myeloma cells. HDAC degrader-2 can be used for the study of myeloma .

HY-171139

*PROTAC HDAC6 degrader* 2**	PROTACs HDAC	Cancer
PROTAC HDAC6 degrader 2 (Compound 1) is a *HDAC6* PROTAC degrader, with IC₅₀ of 0.643 μM. PROTAC HDAC6 degrader 2 promotes ubiquitination and degradation of HDAC6. PROTAC HDAC6 degrader 2 can be used for the research of haematological and solid cancers (Pink: HDAC6 ligand (HY-171141); Blue: E3 ligase CRBN ligand (HY-10984)) .

HY-170495

HDAC6 degrader-5	HDAC Apoptosis Interleukin Related	Inflammation/Immunology
HDAC6 degrader-5 (Compound 6) exhibits inhibitory and degradation activity against *HDAC6, with an IC₅₀* of 4.95 nM and a DC₅₀ of 0.96 nM. HDAC6 degrader-5 inhibits the release of TNF-α, IL-1β and IL-6, blocks the hepatocyte apoptosis. HDAC6 degrader-5 exhibits anti-inflammatory activity in mouse APAP (HY-66005)-induced liver injury models .

HY-171140

*PROTAC HDAC6 degrader* 3**	PROTACs HDAC	Cancer
PROTAC HDAC6 degrader 3 (Compound 4) is a selective inhibitor and degrader for *HDAC6* with an IC₅₀ of 686 nM and a DC₅₀ of 171 nM. PROTAC HDAC6 degrader 3 promotes the acetylation of α-tubulin . (Pink: ligand for target protein (HY-171141); Blue: ligand for E3 ligase VHL (HY-150803))

HY-145815A

JPS014 TFA	PROTACs HDAC Apoptosis	Cancer
JPS014 TFA is a benzamide-based Von Hippel-Lindau (VHL) E3-ligase proteolysis targeting chimeras (PROTAC). JPS014 TFA degrades class I histone deacetylase (HDAC). JPS014 TFA is potent HDAC1/2 degrader correlated with greater total differentially expressed genes and enhanced apoptosis in HCT116 cells .

HY-10585S2

Valproic acid-d15 VPA-d₁₅; 2-Propylpentanoic acid-d₁₅	HDAC Autophagy Mitophagy HIV Notch Endogenous Metabolite	Cancer
Valproic acid-d₁₅ is the deuterium labeled Valproic acid. Valproic acid (VPA; 2-Propylpentanoic Acid) is an HDAC inhibitor, with IC₅₀ in the range of 0.5 and 2 mM, also inhibits HDAC1 (IC₅₀, 400 μM), and induces proteasomal degradation of HDAC2. Valproic acid activates Notch1 signaling and inhibits proliferation in small cell lung cancer (SCLC) cells. Valproic acid sodium salt is used in the treatment of epilepsy, bipolar disorder and prevention of migraine headaches .

HY-157216

HDAC1 Degrader-1	HDAC	Cancer
HDAC1 Degrader-1 (compound 1a) is an *HDAC1* degrader with anticancer activity. HDAC1 Degrader-1 significantly reduces HDAC1 levels in MM.1S multiple myeloma cells .

HY-152133

*PROTAC HDAC6 degrader* 1**	PROTACs HDAC Apoptosis	Cancer
PROTAC HDAC6 degrader (Compound A6) is a potent and selective PROTAC HDAC6 degrader with a DC₅₀ of 3.5 nM. PROTAC HDAC6 degrader shows promising antiproliferative activity via inducing apoptosis in myeloid leukemia cell lines .

HY-171141

HDAC6 ligand-2	Ligands for Target Protein for PROTAC HDAC	Cancer
HDAC6 ligand-2 (Compound 15) is the ligand for *HDAC6* that can be used for synthesis of PROTAC HDAC6 degrader 2 (HY-171139) .

HY-10585S4

Valproic acid-d4-1 VPA-d₄-1; 2-Propylpentanoic acid-d₄-1	Isotope-Labeled Compounds HDAC Autophagy Mitophagy HIV Notch Endogenous Metabolite	Cancer
Valproic acid-d₄-1 is the deuterium labeled Valproic acid. Valproic acid (VPA; 2-Propylpentanoic Acid) is an HDAC inhibitor, with IC₅₀ in the range of 0.5 and 2 mM, also inhibits HDAC1 (IC₅₀, 400 μM), and induces proteasomal degradation of HDAC2. Valproic acid activates Notch1 signaling and inhibits proliferation in small cell lung cancer (SCLC) cells. Valproic acid sodium salt is used in the treatment of epilepsy, bipolar disorder and prevention of migraine headaches .

HY-10585B

Valproic acid sodium (2:1) Sodium Valproate (2:1); VPA sodium (2:1); 2-Propylpentanoic acid sodium (2:1)	HDAC Autophagy Mitophagy HIV Notch Apoptosis Endogenous Metabolite	Infection Neurological Disease Metabolic Disease Cancer
Valproic acid (VPA) sodium (2:1) is an orally active *HDAC* inhibitor, with IC₅₀ in the range of 0.5 and 2 mM, also inhibits *HDAC1* (IC₅₀, 400 μM), and induces proteasomal degradation of *HDAC2. Valproic acid sodium (2:1) activates Notch1* signaling and inhibits proliferation in small cell lung cancer (SCLC) cells. Valproic acid sodium (2:1) is used in the treatment of epilepsy, bipolar disorder, metabolic disease, HIV infection and prevention of migraine headaches .

HY-10585AR

Valproic acid sodium (Standard) Sodium Valproate (Standard); VPA sodium (Standard); 2-Propylpentanoic acid sodium (Standard)	Organoid Reference Standards HDAC Autophagy Mitophagy HIV Notch Apoptosis Endogenous Metabolite	Infection Neurological Disease Metabolic Disease Cancer
Valproic acid (sodium) (Standard) is the analytical standard of Valproic acid (sodium). This product is intended for research and analytical applications. Valproic acid (Sodium Valproate) sodium is an orally active *HDAC* inhibitor, with IC₅₀ in the range of 0.5 and 2 mM, also inhibits *HDAC1* (IC₅₀, 400 μM), and induces proteasomal degradation of *HDAC2. Valproic acid sodium activates Notch1* signaling and inhibits proliferation in small cell lung cancer (SCLC) cells. Valproic acid sodium is used in the treatment of epilepsy, bipolar disorder, metabolic disease, HIV infection and prevention of migraine headaches .

HY-174444

*PROTAC HDAC* degrader-2**	PROTACs HDAC	Cancer
PROTAC HDAC degrader-2 is a selective *IIb HDACs* PROTAC** degrader, with DC₅₀s of 13 nM for *HDAC6, 29 nM for HDAC10, respectively. PROTAC HDAC* degrader-2 exhibits low cytotoxicity against hematological and solid cancer cell lines. PROTAC HDAC degrader-2 can be used for the chemical knockdown of class IIb HDACs. ( Pink: HDAC ligand : (HY-174471), Blue: E3 ligase CRBN Ligand (HY-131717), E3 ligase ligand-linker conjugate (HY-174473)) .

HY-177758

*PROTAC HDAC6 degrader* 8**	PROTACs HDAC	Cancer
HDAC6 degrader-6 (Compound 11b) is a potent and selective HDAC6 PROTAC degrader with a DC₅₀ of 1.9 nM. HDAC6 degrader-6 has no effect on the protein levels of other HDAC family members and does not degrade IKZF1, IKZF3, and GSPT1. HDAC6 degrader-6 can be used to study multiple myeloma (Pink: HDAC6 ligand (HY-177776); Blue: CRBN ligand (HY-W998281); Black: Linker) .

HY-176904

JPS004	PROTACs HDAC Apoptosis	Cancer
JPS004 is a HDAC1-3 PROTAC degrader. JPS004 can induce degradation of HDAC1-3 and induce histone acetylation. JPS004 can induce cancer cells apoptosis. JPS004 can be used for the research of cancer . (Structure Note: Pink: HDAC1-3 ligand (HY-50934); Blue: VHL ligand (HY-125845); HDAC1-3 ligand-Linker: (HY-176905))

HY-145818

JPS035	HDAC PROTACs	Cancer
JPS035 is a benzamide-based Von Hippel-Lindau (VHL) E3-ligase proteolysis targeting chimeras (PROTAC). JPS035 degrades class I histone deacetylase (HDAC). JPS035 is potent HDAC1/2 degrader correlated with greater total differentially expressed genes and enhanced apoptosis in HCT116 cells .

HY-145815

JPS014	HDAC PROTACs	Cancer
JPS014 is a benzamide-based Von Hippel-Lindau (VHL) E3-ligase proteolysis targeting chimeras (PROTAC). JPS014 degrades class I histone deacetylase (HDAC). JPS014 is potent HDAC1/2 degrader correlated with greater total differentially expressed genes and enhanced apoptosis in HCT116 cells .

HY-173266

TO-1187	PROTACs HDAC	Neurological Disease Cancer
TO-1187 is a selective *HDAC6* PROTAC degrader (DC₅₀: 5.81 nM). TO-1187 promotes the ubiquitination and degradation of HDAC6 and can be used in the study of hematological malignancies and solid tumors (Pink: HDAC6 ligand (HY-173386); Blue: CRBN ligase ligand (HY-41547); Black: linker (HY-140212)) .

HY-145816

JPS016	PROTACs HDAC Apoptosis PINK1/Parkin Autophagy Reactive Oxygen Species (ROS)	Cardiovascular Disease Cancer
JPS016 is a class I histone deacetylase (HDAC) PROTAC inhibitor. JPS016 recruits the VHL E3 ligase (Ligands for E3 Ligase) to mediate the ubiquitination and proteasomal degradation of *HDAC1, HDAC2* and *HDAC3. JPS016 reduces the viability of colon cancer cells and induces Apoptosis. JPS016 activates the PINK1/Parkin* mitochondrial Autophagy pathway, enhances cardiomyocyte viability, alleviates mitochondrial damage, and reduces mitochondrial ROS production in cells. JPS016 is applicable to research related to colon cancer and sepsis cardiomyopathy .

HY-118160

PPM-18 NSC 73233	NO Synthase Drug Derivative IKK NF-κB HDAC Reactive Oxygen Species (ROS) AMPK mTOR PI3K Akt Autophagy Apoptosis	Cardiovascular Disease Infection Neurological Disease Inflammation/Immunology Cancer
PPM-18 (NSC 73233) is a Vitamin K (HY-B2172) analog. PPM-18 prevents LPS-induced IκBα degradation, thereby inhibiting NF-κB activation and nuclear translocation of NF-κB. PPM-18 inhibits LPS-induced nitrite production and iNOS expression. PPM-18 inhibits *HDAC6. PPM-18 induces ROS* accumulation, activates AMPK, inhibits the mTORC1 and PI3K/AKT pathways, initiates Autophagy, and induces Apoptosis. PPM-18 suppresses seizures in zebrafish and mouse epilepsy models. PPM-18 prevents LPS-induced lethal toxicity and delayed hypotension. PPM-18 exhibits anticancer activity against leukemia and bladder cancer. PPM-18 can be used in research related to septic shock, bladder cancer and atherosclerosis .

HY-177776

HDAC-IN-97	Ligands for Target Protein for PROTAC HDAC	Cancer
HDAC-IN-97 is a PROTAC HDAC6 degrader-6that can be used for synthesis of PROTACs, such as HDAC6 degrader-6 (HY-177758). HDAC6 degrader-6 is a potent HDAC6 PROTAC degrader with anticancer activity .

HY-123971

HDAC6 degrader-4	HDAC PROTACs	Cancer
HDAC6 degrader-4 is a PROTAC and a selective *HDAC6* degrader consists of a non-selective HDAC inhibitor and thalidomide-type E3 ligase ligand. HDAC6 degrader-4 can be used for cancer research .

HY-177759

*PROTAC HDAC6 degrader* 9**	PROTACs HDAC	Cancer
PROTAC HDAC6 degrader 9 is a selective HDAC6 PROTAC degrader. PROTAC HDAC6 degrader 9 can be used for the research cancers related to HDAC6 abnormalities, such as multiple myeloma .

HY-174471

HDAC-IN-90	HDAC Ligands for Target Protein for PROTAC	Cancer
HDAC-IN-90 is the ligand for HDAC6/10 that can be used for synthesis of PROTAC HDAC degrader-2 (HY-174444) .

HY-176207

HDAC degrader-1	ByeTAC HDAC	Cancer
HDAC6 degrader-6 (compound 10c) is a ByeTAC protein degrader targeting *HDAC6, with IC₅₀* values of 0.034 μM, 0.166 μM, 0.703 μM, and 0.293 μM for *HDAC6, HDAC1, HDAC2, and HDAC3, respectively. HDAC6 degrader-6 induces cell apoptosis* and can be used for the study of multiple myeloma(Blue: USP14 ligand HY-159808; Pink: HDAC ligand HY-176209; Black: linker HY-W016871)

HY-174401

*PROTAC HDAC6 degrader* 5**	PROTACs HDAC Ligands for E3 Ligase	Cancer
PROTAC HDAC6 degrader 5 (Compound 5a) is a highly selective PROTAC targeting *HDAC6. PROTAC HDAC6 degrader* 5 can effectively degrade *HDAC6* in cells (IC₅₀ = 43 nM). PROTAC HDAC6 degrader 5 reduces *HDAC6* levels through proteasome- and CRBN-dependent mechanisms (Pink: Target protein ligand (HY-174408), Target protein ligand + linker (HY-174409); Blue: Pomalidomide (HY-10984), Pomalidomide 4'-alkylC3-azide (HY-139341)) .

HY-179422

HDAC6-IN-68	Ligands for Target Protein for PROTAC HDAC	Inflammation/Immunology
HDAC6-IN-68 is an *HDAC6* PROTAC ligand. HDAC6-IN-68 can be used to synthesize PROTAC HDAC6 degrader 7 (HY-179421) .

HY-179421

*PROTAC HDAC6 degrader* 7**	PROTACs HDAC NF-κB NOD-like Receptor (NLR) Interleukin Related TNF Receptor	Inflammation/Immunology
PROTAC HDAC6 degrader 7 is an orally active, highly efficient, and selective PROTAC degrader targeting histone deacetylase 6 (HDAC6) (IC₅₀ = 118 nM). PROTAC HDAC6 degrader 7 can eliminate both the catalytic and zinc-finger ubiquitin-binding domain. PROTAC HDAC6 degrader 7 inhibits NLRP3 inflammasome assembly and activation, as well as blocks NF-κB signaling, thereby reducing the transcription and release of key inflammatory factors. PROTAC HDAC6 degrader 7 can reduce the mRNA levels of NLRP3, pro-IL-1β, TNF-α, and IL-6. PROTAC HDAC6 degrader 7 can be used for the study of inflammatory bowel disease (IBD) .

HY-163845

YX862	PROTACs HDAC	Cancer
YX862 is a selective *HDAC8* PROTAC degrader and induces the degradation of *HDAC8* with maximum degradation ＞ 95% at 250 nM in MDA-MB-231 cells(Sturcture Note:(Blue: VHL E3 ligand (HY-112078), Black: linker；Pink: HDAC8 inhibitor (HY-163846)) .

HY-174408

HDAC6 ligand-5	Ligands for Target Protein for PROTAC HDAC	Cancer
HDAC6 ligand-5 is a binding ligand of *HDAC6* and can be used to synthesize PROTACs such as PROTAC HDAC6 degrader 5 .

HY-174877

*PROTAC HDAC6 degrader* 6**	PROTACs HDAC	Cancer
PROTAC HDAC6 degrader 6 (Compound 12) is a selective *HDAC6*-targeting photochemically targeting chimeras (PHOTACs) (subset of PROTAC) degrader with a ∼50% D_max only upon activation to its cis-state with 390 nm light irradiation . Pink: HDAC6 ligand; Blue: CRBN ligase ligand (HY-A0003); Black: linker

HY-159172

HDAC3-IN-4	HDAC	Cancer
HDAC3-IN-4 is a selective and orally active *HDAC3* inhibitor with an IC₅₀ of 89 nM. HDAC3-IN-4 induces the degradation of PD-L1 by regulating cathepsin B (CTSB) in the lysosomes, with a DC₅₀ of 5.7 μM. HDAC3-IN-4 shows better selectivity for HDAC3 over HDAC1, HDAC6, HDAC7, and HDAC8 .

HY-174409

HDAC6 ligand-Linker Conjugate 1	Target Protein Ligand-Linker Conjugates HDAC	Cancer
HDAC6 ligand-linker conjugate 1 is a conjugate of *HDAC6* ligand and linker, which can be used to synthesize PROTACs such as PROTAC HDAC6 degrader 5 (HY-174401) .

Cat. No.	Product Name	Type

HY-10585AG

Valproic acid sodium

Sodium Valproate; VPA sodium; 2-Propylpentanoic acid sodium

Fluorescent Dyes

Valproic acid (Sodium Valproate) sodium is an orally active HDAC inhibitor, with IC₅₀ in the range of 0.5 and 2 mM, also inhibits HDAC1 (IC₅₀, 400 μM), and induces proteasomal degradation of HDAC2. Valproic acid sodium activates Notch1 signaling and inhibits proliferation in small cell lung cancer (SCLC) cells. Valproic acid sodium is used in the treatment of epilepsy, bipolar disorder, metabolic disease, HIV infection and prevention of migraine headaches .

Cat. No.	Product Name	Type

HY-10585AG

Valproic acid sodium

Sodium Valproate; VPA sodium; 2-Propylpentanoic acid sodium

Biochemical Assay Reagents

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-10585

Valproic acid Maximum Cited Publications 65 Publications Verification VPA; 2-Propylpentanoic acid; Dipropylacetic acid	Infection Structural Classification Classification of Application Fields Ketones, Aldehydes, Acids Metabolic Disease Endogenous metabolite Disease Research Fields Source Classification Cancer	Organoid HDAC Autophagy Mitophagy HIV Notch Apoptosis Endogenous Metabolite
Valproic acid (VPA) is an orally active *HDAC* inhibitor, with IC₅₀ in the range of 0.5 and 2 mM. Valproic acid inhibits *HDAC1* (IC₅₀, 400 μM), and induces proteasomal degradation of *HDAC2. Valproic acid activates Notch1* signaling and inhibits proliferation in small cell lung cancer (SCLC) cells. Valproic acid is used in the epilepsy, bipolar disorder, metabolic disease, HIV infection and prevention of migraine headaches .

HY-10585A

Valproic acid sodium Maximum Cited Publications 65 Publications Verification Sodium Valproate; VPA sodium; 2-Propylpentanoic acid sodium	Infection Classification of Application Fields Ketones, Aldehydes, Acids Metabolic Disease Endogenous metabolite Disease Research Fields Source Classification Cancer	Organoid HDAC Autophagy Mitophagy HIV Notch Apoptosis Endogenous Metabolite
Valproic acid (Sodium Valproate) sodium is an orally active *HDAC* inhibitor, with IC₅₀ in the range of 0.5 and 2 mM, also inhibits *HDAC1* (IC₅₀, 400 μM), and induces proteasomal degradation of *HDAC2. Valproic acid sodium activates Notch1* signaling and inhibits proliferation in small cell lung cancer (SCLC) cells. Valproic acid sodium is used in the treatment of epilepsy, bipolar disorder, metabolic disease, HIV infection and prevention of migraine headaches .

HY-N0857

Deoxyandrographolide 1 Publications Verification	Structural Classification Acanthaceae Simsia foetida (Cav.) S.F.Blake Terpenoids Diterpenoids Plants Source Classification	GLUT HDAC Virus Protease PI3K AMPK Akt Histone Demethylase MDM-2/p53 IFNAR Reactive Oxygen Species (ROS)
Deoxyandrographolide is an orally active lactone found in the Andrographis paniculata Nees. Deoxyandrographolide shows a K_D of 38.4 μM of *HDAC1. Deoxyandrographolide enhances GLUT4* plasma membrane translocation, activates PI3K and AMPK-dependent signaling pathways, suppresses fasting blood glucose, serum insulin, triglycerides, and LDL-cholesterol levels. Deoxyandrographolide enhances HDAC1 expression via inhibited ubiquitination degradation, represses H3K4me3, improves chromosome stability, and restrains aging biomarkers p16, p21, γH2A.X, p53 and ROS production. Deoxyandrographolide interacts with Foot-and-Mouth Disease Virus 3Cpro active site, inhibits protease and IFN-antagonist activity, derepresses ISG expression, and inhibits viral replication. Deoxyandrographolide can be used for the researches of type 2 diabetes mellitus, vascular senescence and virus infection .

HY-10585B

Valproic acid sodium (2:1) Sodium Valproate (2:1); VPA sodium (2:1); 2-Propylpentanoic acid sodium (2:1)	Infection Classification of Application Fields Ketones, Aldehydes, Acids Metabolic Disease Endogenous metabolite Disease Research Fields Source Classification Cancer	HDAC Autophagy Mitophagy HIV Notch Apoptosis Endogenous Metabolite
Valproic acid (VPA) sodium (2:1) is an orally active *HDAC* inhibitor, with IC₅₀ in the range of 0.5 and 2 mM, also inhibits *HDAC1* (IC₅₀, 400 μM), and induces proteasomal degradation of *HDAC2. Valproic acid sodium (2:1) activates Notch1* signaling and inhibits proliferation in small cell lung cancer (SCLC) cells. Valproic acid sodium (2:1) is used in the treatment of epilepsy, bipolar disorder, metabolic disease, HIV infection and prevention of migraine headaches .

HY-10585AR

Valproic acid sodium (Standard) Sodium Valproate (Standard); VPA sodium (Standard); 2-Propylpentanoic acid sodium (Standard)	Structural Classification Ketones, Aldehydes, Acids Endogenous metabolite Source Classification	Organoid Reference Standards HDAC Autophagy Mitophagy HIV Notch Apoptosis Endogenous Metabolite
Valproic acid (sodium) (Standard) is the analytical standard of Valproic acid (sodium). This product is intended for research and analytical applications. Valproic acid (Sodium Valproate) sodium is an orally active *HDAC* inhibitor, with IC₅₀ in the range of 0.5 and 2 mM, also inhibits *HDAC1* (IC₅₀, 400 μM), and induces proteasomal degradation of *HDAC2. Valproic acid sodium activates Notch1* signaling and inhibits proliferation in small cell lung cancer (SCLC) cells. Valproic acid sodium is used in the treatment of epilepsy, bipolar disorder, metabolic disease, HIV infection and prevention of migraine headaches .

Cat. No.	Product Name	Chemical Structure

HY-10585S

Valproic acid-d4

1 Publications Verification

Valproic acid-d₄ is the deuterium labeled Valproic acid. Valproic acid (VPA; 2-Propylpentanoic Acid) is an HDAC inhibitor, with IC₅₀ in the range of 0.5 and 2 mM, also inhibits HDAC1 (IC₅₀, 400 μM), and induces proteasomal degradation of HDAC2. Valproic acid activates Notch1 signaling and inhibits proliferation in small cell lung cancer (SCLC) cells. Valproic acid sodium salt is used in the treatment of epilepsy, bipolar disorder and prevention of migraine headaches .

HY-10585S1

Valproic acid-d6

Valproic acid-d₆ is the deuterium labeled Valproic acid. Valproic acid (VPA; 2-Propylpentanoic Acid) is an HDAC inhibitor, with IC₅₀ in the range of 0.5 and 2 mM, also inhibits HDAC1 (IC₅₀, 400 μM), and induces proteasomal degradation of HDAC2. Valproic acid activates Notch1 signaling and inhibits proliferation in small cell lung cancer (SCLC) cells. Valproic acid sodium salt is used in the treatment of epilepsy, bipolar disorder and prevention of migraine headaches .

HY-10585S2

Valproic acid-d15

Valproic acid-d₁₅ is the deuterium labeled Valproic acid. Valproic acid (VPA; 2-Propylpentanoic Acid) is an HDAC inhibitor, with IC₅₀ in the range of 0.5 and 2 mM, also inhibits HDAC1 (IC₅₀, 400 μM), and induces proteasomal degradation of HDAC2. Valproic acid activates Notch1 signaling and inhibits proliferation in small cell lung cancer (SCLC) cells. Valproic acid sodium salt is used in the treatment of epilepsy, bipolar disorder and prevention of migraine headaches .

HY-10585S4

Valproic acid-d4-1

Valproic acid-d₄-1 is the deuterium labeled Valproic acid. Valproic acid (VPA; 2-Propylpentanoic Acid) is an HDAC inhibitor, with IC₅₀ in the range of 0.5 and 2 mM, also inhibits HDAC1 (IC₅₀, 400 μM), and induces proteasomal degradation of HDAC2. Valproic acid activates Notch1 signaling and inhibits proliferation in small cell lung cancer (SCLC) cells. Valproic acid sodium salt is used in the treatment of epilepsy, bipolar disorder and prevention of migraine headaches .

HY-10585AS1

Valproic acid-d14 sodium

Valproic acid-d₁₄ (sodium) is deuterium labeled Valproic acid (sodium). Valproic acid sodium salt (Sodium Valproate) is an HDAC inhibitor, with IC50 in the range of 0.5 and 2 mM, also inhibits HDAC1 (IC50, 400 μM), and induces proteasomal degradation of HDAC2. Valproic acid sodium salt activates Notch1 signaling and inhibits proliferation in small cell lung cancer (SCLC) cells. Valproic acid sodium salt is used in the treatment of epilepsy, bipolar disorder and prevention of migraine headaches.

HY-10585AS

Valproic acid-d7 sodium

Valproic acid-d₇ (sodium) is the deuterium labeled Valproic acid (sodium salt). Valproic acid sodium salt (Sodium Valproate) is an HDAC inhibitor, with IC₅₀ in the range of 0.5 and 2 mM, also inhibits HDAC1 (IC₅₀, 400 μM), and induces proteasomal degradation of HDAC2. Valproic acid sodium salt activates Notch1 signaling and inhibits proliferation in small cell lung cancer (SCLC) cells. Valproic acid sodium salt is used in the treatment of epilepsy, bipolar disorder and prevention of migraine headaches .

HY-10585S3

Valproic acid-d4 sodium

Valproic acid-d₄ (sodium) is the deuterium labeled Valproic acid. Valproic acid (VPA; 2-Propylpentanoic Acid) is an HDAC inhibitor, with IC50 in the range of 0.5 and 2 mM, also inhibits HDAC1 (IC50, 400 μM), and induces proteasomal degradation of HDAC2. Valproic acid activates Notch1 signaling and inhibits proliferation in small cell lung cancer (SCLC) cells. Valproic acid sodium salt is used in the treatment of epilepsy, bipolar disorder and prevention of migraine headaches.

Cat. No.	Product Name		Classification

HY-172360

HDAC6 ligand-3		Alkynes
HDAC6 ligand-3 is a ligand for *HDAC6* that can be used as target protein ligand for synthesis of PROTAC HDAC6 degrader 4 (HY-172359) .

HY-174473

Thalidomide-NH-alkynes		Alkynes
Thalidomide-NH-alkynes is a synthesized E3 ligase ligand-linker conjugate that can be used for synthesis of PROTAC HDAC degrader-2 (HY-174444) .

HY-172361

Thalidomide-F-NH-C6-adize		Azide
Thalidomide-F-NH-C6-adize is the conjugate of an E3 ligase (Cereblon) ligand and a linker, and can be used for synthesis of PROTAC HDAC6 degrader 4 (HY-172359) .

HY-181043

CRBN ligand-895-PEG2-N3		Azide
CRBN ligand-895-PEG2-N3 (Compound 15) is a synthetic E3 ligase linker conjugate that can be used for the synthesis of PROTACs, such as PROTAC HDAC8 Degrader-4 (HY-181024) .

Targets Recommended: HDAC

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-10585AG

Valproic acid sodium Sodium Valproate; VPA sodium; 2-Propylpentanoic acid sodium	Organoid HDAC Autophagy Mitophagy HIV Notch Apoptosis Endogenous Metabolite	Infection Neurological Disease Metabolic Disease Cancer
Valproic acid (Sodium Valproate) sodium is an orally active *HDAC* inhibitor, with IC₅₀ in the range of 0.5 and 2 mM, also inhibits *HDAC1* (IC₅₀, 400 μM), and induces proteasomal degradation of *HDAC2. Valproic acid sodium activates Notch1* signaling and inhibits proliferation in small cell lung cancer (SCLC) cells. Valproic acid sodium is used in the treatment of epilepsy, bipolar disorder, metabolic disease, HIV infection and prevention of migraine headaches .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

HDAC degraders

Inhibitors & Agonists

Fluorescent Dyes

Biochemical Assay Reagents

NaturalProducts

Isotope-Labeled Compounds

Click Chemistry

GMP Molecules

Natural
Products